Ted Kellner Issues Letter to AIM ImmunoTech (AIM)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/30/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- BioNTech ends colorectal cancer mRNA therapy trial early
- Needham sees mature node semiconductor strength in latest tracker
AIM’s Clinical Strategy Under Incumbent Board Has Totally Failed
December 11, 2024 7:30 AM ESTIncumbent Boards Claims of Progress Are Not Credible or Supported by Data
AIM Maintains Relationship with CRO Co-Founded by a Convicted Felon Who Deceived Investors about the Timeline and Status of Regulatory Submissions to the U.S. FDA
According to ISS The lack of transparency gives the impression that the companys pipeline is more advanced and that the company is more involved than it actually is1
Kellner Group Owns 5.04% of Outstanding Shares and is Fully Aligned with... More
